Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Enapotamab vedotin |
| Synonyms | |
| Therapy Description |
Enapotamab vedotin (HuMax-Axl-ADC) is an antibody-drug conjugate comprising an AXL targeted antibody linked to the anti-microtubule compound MMAE, which potentially decreases tumor growth (J Clin Oncol 35, 2017 (suppl; abstr TPS2605), PMID: 32148495, PMID: 31600169). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Enapotamab vedotin | AXL-107-MMAE|HuMax-Axl-ADC | AXL Antibody 5 | Enapotamab vedotin (HuMax-Axl-ADC) is an antibody-drug conjugate comprising an AXL targeted antibody linked to the anti-microtubule compound MMAE, which potentially decreases tumor growth (J Clin Oncol 35, 2017 (suppl; abstr TPS2605), PMID: 32148495, PMID: 31600169). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL positive | Advanced Solid Tumor | predicted - sensitive | Enapotamab vedotin | Preclinical - Pdx | Actionable | In a preclinical study, Enapotamab vedotin (HuMax-Axl-ADC) inhibited tumor growth in solid tumor xenograft models, including induction of tumor regression in solid tumor patient-derived xenograft (PDX) models expressing Axl in a subset of tumor cells (J Clin Onc 2015 33:15_suppl, 3066). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02988817 | Phase Ib/II | Enapotamab vedotin | HuMax-AXL-ADC Safety Study in Patients With Solid Tumors | Completed | USA | NLD | GBR | ESP | DNK | BEL | 0 |